(Q37833109)

24 August 2017

1 reference

title

The molecular pathogenesis and management of bronchial carcinoids (English)

1 reference

24 August 2017

0 references

2

Ashley Grossman

1 reference

24 August 2017

Mehtap Cakir

1

1 reference

PubMed ID

21275849

24 August 2017

language of work or name

English

0 references

publication date

29 January 2011

1 reference

Expert Opinion on Therapeutic Targets

24 August 2017

1 reference

24 August 2017

15

1 reference

24 August 2017

4

1 reference

24 August 2017

457-491

1 reference

Genetics of neuroendocrine and carcinoid tumours

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Lung tumours with neuroendocrine differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Pulmonary neuroendocrine/carcinoid tumors: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Bronchopulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Molecular genetics of multiple endocrine neoplasia types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of the alpha7 nicotinic acetylcholine receptor in human lung cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of G-protein inwardly rectifying potassium channels (GIRKs) in lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Analysis of ErbB receptors in pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Unique susceptibility of a human lung carcinoid tumor cell line to infection with BK virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Genetic changes in the spectrum of neuroendocrine lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Molecular analysis of the HuD gene in neuroendocrine lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Differential inactivation of caspase-8 in lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Evaluation of an inhibitor of DNA methylation, 5-aza-2'-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Bronchial typical carcinoid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Immunohistochemical localization of somatostatin receptors sst2A in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Dopamine receptor expression and function in corticotroph ectopic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Lack of C-erbB-2 protein expression in pulmonary carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

P63 expression in lung carcinoma: a tissue microarray study of 408 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Is small cell lung cancer the perfect target for anti-telomerase treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Gastrin-releasing-peptide in neuroendorine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Nuclear overexpression of the E2F3 transcription factor in human lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Somatostatin receptor scintigraphy for bronchial carcinoid follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Octreoscan in patients with bronchial carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Typical and atypical bronchopulmonary carcinoid tumors on FDG PET/CT imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Efficacy of 99mTc-EDDA/HYNIC-TOC scintigraphy in differential diagnosis of solitary pulmonary nodules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

[99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Atypical carcinoid tumor detected incidentally on Ttc-99m sestamibi myocardial perfusion scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Experience in treatment of metastatic pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Antiproliferative effects of the Ca2/calmodulin antagonist B859–35 and the Ca2-channel blocker Verapamil on human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Alteration of the E-cadherin/?-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.555403

10.1517/14728222.2011.555403

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21275849